{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:50:18Z","timestamp":1788522618910,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabres.2026.113147","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:37:41Z","timestamp":1770449861000},"page":"113147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["SGLT2 inhibitors improve subclinical left ventricular systolic function independent of body mass index in patients with type 2 diabetes: A prospective strain imaging study"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-5414","authenticated-orcid":false,"given":"\u00d6mer","family":"K\u00fcmet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-3743","authenticated-orcid":false,"given":"Fuat","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3032-5031","authenticated-orcid":false,"given":"Ozan","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-4061","authenticated-orcid":false,"given":"Veysi","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-0657","authenticated-orcid":false,"given":"Ahmet Ferhat","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-5414","authenticated-orcid":false,"given":"G\u00f6rkem","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-6700","authenticated-orcid":false,"given":"Emrah","family":"\u00d6zbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113147_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113147_b0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.diabres.2026.113147_b0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.diabres.2026.113147_b0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113147_b0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005521","article-title":"Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: the Copenhagen City Heart Study","volume":"10","author":"Biering-S\u00f8rensen","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.diabres.2026.113147_b0035","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/heartjnl-2014-305538","article-title":"Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction","volume":"100","author":"Kalam","year":"2014","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.diabres.2026.113147_b0040","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.echo.2011.07.017","article-title":"Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy?","volume":"24","author":"Ernande","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"10.1016\/j.diabres.2026.113147_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.echo.2012.10.008","article-title":"Normal ranges of left ventricular strain: a meta-analysis","volume":"26","author":"Yingchoncharoen","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"issue":"10166","key":"10.1016\/j.diabres.2026.113147_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.diabres.2026.113147_b0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113147_b0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113147_b0065","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"21","key":"10.1016\/j.diabres.2026.113147_b0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/dom.15324","article-title":"Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance","volume":"26","author":"Nesti","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2026.113147_b0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","article-title":"Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence","volume":"17","author":"Tan","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.diabres.2026.113147_b0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"issue":"27","key":"10.1016\/j.diabres.2026.113147_b0095","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.diabres.2026.113147_b0100","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.amjcard.2009.06.063","article-title":"Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus","volume":"104","author":"Ng","year":"2009","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2008.06.091","article-title":"Echocardiographic strain and strain rate imaging\u2014clinical applications","volume":"132","author":"Dandel","year":"2009","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113147_b0110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1253\/circj.CJ-15-0012","article-title":"Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients","volume":"79","author":"Enomoto","year":"2015","journal-title":"Circ J"},{"issue":"15","key":"10.1016\/j.diabres.2026.113147_b0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2026.113147_b0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2026.113147_b0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.diabres.2026.113147_b0130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0135","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabres.2026.113147_b0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113147_b0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: the sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.diabres.2026.113147_b0150","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.diabres.2026.113147_b0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.2012.9282","article-title":"Association of weight status with mortality in adults with incident diabetes","volume":"308","author":"Carnethon","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113147_b0160","doi-asserted-by":"crossref","unstructured":"Nesti L, Pugliese NR, Sciuto P, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial.Cardiovasc Diabetol. 2022;21(1):181. Published 2022 Sep 12.","DOI":"10.1186\/s12933-022-01618-1"},{"issue":"21","key":"10.1016\/j.diabres.2026.113147_b0165","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113147_b0170","first-page":"1068","article-title":"Relationship between weight loss and cardiovascular outcomes with semaglutide in the SUSTAIN and PIONEER trials","volume":"25","author":"Pratley","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"47","key":"10.1016\/j.diabres.2026.113147_b0175","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.diabres.2026.113147_b0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1076029615569568","article-title":"The relation between atherosclerosis and the neutrophil-lymphocyte ratio","volume":"22","author":"Balta","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"19","key":"10.1016\/j.diabres.2026.113147_b0185","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:41:45Z","timestamp":1779093705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S0168822726000665"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113147","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors improve subclinical left ventricular systolic function independent of body mass index in patients with type 2 diabetes: A prospective strain imaging study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113147"}}